What people are saying.

October 6, 2016

Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)

September 29, 2016

CELL DESIGN LABS ANNOUNCES PEER-REVIEWED PUBLICATION VALIDATING ABILITY TO PROGRAM IMMUNE CELLS TO TREAT CANCER AND AUTOIMMUNE DISEASE

September 26, 2016

Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL)

September 26, 2016

Capricor Therapeutics Awarded $2.4 Million from U.S. Department of Defense to Support Manufacturing Process Development for Therapeutic Exosomes

September 21, 2016

Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds

September 20, 2016

Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS

August 16, 2016

Arno Completes $2.8 Million Private Placement

July 27, 2016

Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies

July 25, 2016

Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies

July 12, 2016

Sienna Biopharmaceuticals Announces Second Closing of Series A Financing

June 20, 2016

Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)

June 20, 2016

Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility

June 16, 2016

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

June 6, 2016

Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma

June 6, 2016

Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)

June 6, 2016

Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma

June 2, 2016

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies

June 2, 2016

Cell Design Labs Executes Series of Private Financings

June 2, 2016

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies

May 5, 2016

UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting

May 2, 2016

Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

April 28, 2016

Sienna Biopharmaceuticals Announces $34 Million Series A Financing

April 19, 2016

Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA

April 19, 2016

Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting

April 4, 2016

Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial